1. Scrip
  2. >>Business
  3. >>Earnings

Bausch Says B+L Spinout Or IPO Could Occur During ‘October Timeframe’

 
• By Joseph Haas

During Bausch Health’s first quarter earnings call, CEO Papa said he’ll lead Bausch + Lomb following the corporate split. Overall the company reported flat revenues, but said its pandemic rebound is ongoing.

Sprout in treetrunk
Bausch Health hopes growth is sprouting after the pandemic issues of 2020 • Source: Alamy

Bausch Health Companies Inc. CEO Joseph Papa told investors on 4 May that the planned separation into two companies is making progress and either a spinout or initial public offering of the Bausch + Lomb Inc. eye care business could take place as early as October. Papa, who has been overseeing Bausch Health’s transformation away from the debt, drug price controversy and ill-fitting components of predecessor firm Valeant since 2016, also said he would lead the B+L spinout company.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Taxes, Not Tariffs, Influence US Manufacturing, J&J CEO Says

 
• By Jessica Merrill

The big pharma forecast a $400m expense this year related to tariffs, but those estimates only reflect medtech tariffs already announced, not potential pharma tariffs.

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Regulatory And Macroeconomic Uncertainty Hang Over Q1 Earnings Season

 
• By Jessica Merrill

As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.

US Pharma Tariff Reprieve Appears Short-Lived

 
• By Jessica Merrill

Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.

More from Business

Pfizer’s Danuglipron Is Done, Sparking M&A Speculation

 
• By Jessica Merrill

The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.

Scancell Signs UK Match-Making Pact For Melanoma Vaccine

 
• By Kevin Grogan

The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Trump’s tariff rollercoaster; regulatory, economic uncertainties hang over Q1 earnings; IPOs rise in Q1 but may slow; Chinese deal-making matures; and AstraZeneca talks about Chinese innovation.